Lira-cel continues to exhibit positive survival data in ongoing Phase 1 clinical trial

SAN JOSE, Calif., April 22, 2026 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ:ANIX), a biotechnology company focused on the treatment and prevention of cancer, today announced that Cheryl Cox, MHA, Operations Director of the Cell Therapies and Gene Expression Engineering Facility at Moffitt Cancer Center, will be presenting at the International Society for Cell & Gene Therapy (ISCT) 2026 Annual Meeting, being held May 6 – 9, 2026, in Dublin, Ireland.

Ms. Cox's presentation, titled "Phase 1 clinical trial of autologous T cells genetically engineered with a chimeric receptor to target the follicle-stimulating hormone receptor (FSHR) in recurrent ovarian cancer," will discuss the clinical trial design and objectives, as well as the current status of Anixa's ongoing Phase 1 clinical trial of lira-cel.

The ISCT 2026 Annual Meeting will bring together thousands of global experts in cell and gene therapy. This event is recognized as the largest conference focused on translating cell and gene therapies from research to clinical practice. The four-day program will feature hundreds of speakers, cutting edge scientific presentations, and interactive sessions covering advances in areas such as gene editing, bioprocessing, and clinical translation, alongside extensive networking opportunities and industry showcases.